Novel treatment of inflammatory diseases
LipUm has discovered a novel treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases by a unique
therapeutic antibody directed towards the Bile Salt-Stimulated Lipase, which has been identified as a key target to block and
thereby inhibit the inflammatory process and prevent joint destruction.
The global prevalence of RA is 0.3-1%, and it is twice as common among woman than men, and the risk to develop the
condition increases by age. Frequently, other serious diseases are co-occurring with RA and according to the World Health
Organisation 50% of patients in developed countries are unable to hold a full-time job within ten years after disease onset.
The societal economic burden due to the disease is thus enormous, while health economic calculations estimate the cost for
pharmaceuticals to less than 20% of the total cost. Still, the drug market value growth between 2014 and 2019 is expected to
increase by 55% to 30 billion USD.
The introduction and use of biologicals such as the TNF-alfa inhibitors constituted a major achievement in the treatment, but
with time it has also been concluded that 1/3 of patients are not responding and another 1/3 experience only a transient
improvement. As these biologicals suppress the immune system such drugs should not be combined with other
immunosuppressants, as it may create adverse health effects. Key opinion leaders have therefore pointed out the need for
drugs that have a complementary therapeutic mechanism.
This is the gap that LipUm intends to fill and a tentative strategy is to apply for a orphan drug designation for juvenile
idiopathic arthritis that affect children, frequently with extreme disability and poor quality of life. As an orphan drug our unique
biological more rapidly could contribute to improved treatment of the 85,000 children diagnosed with the disease in Europe.